LNTH 📈 Lantheus Holdings - Overview

Lantheus Holdings, Inc. is a company that specializes in developing, manufacturing, and commercializing a range of diagnostic and therapeutic products used to assist clinicians in diagnosing and treating various diseases, including heart conditions, cancer, and other disorders, on a global scale. Their product portfolio includes DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams to improve image quality, and TechneLite, a technetium generator used in nuclear medicine procedures to produce radiopharmaceuticals. Additionally, they offer Xenon-133, a radiopharmaceutical gas used to assess pulmonary function, and Neurolite, an injectable imaging agent used to identify areas of reduced blood flow in the brain due to stroke.

The company's product line also includes Cardiolite, an injectable Tc-99m-labeled imaging agent used to assess blood flow to the heart muscle, and PYLARIFY, an F 18-labeled PSMA-targeted PET imaging agent used to image PSMA-positive lesions in men with prostate cancer. Furthermore, Lantheus offers the Automated Bone Scan Index, a software that uses artificial neural networks to calculate the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions. They also provide RELISTOR, a treatment for opioid-induced constipation, and aPROMISE, an artificial intelligence medical device software, as well as PYLARIFY AI, an AI-based medical device software used to perform quantitative assessments of PSMA PET/CT images in prostate cancer.

Lantheus has a robust pipeline of products in development, including 1095, a PSMA-targeted iodine-131-labeled small molecule, PNT2002, a radiopharmaceutical therapy for the treatment of metastatic castration-resistant prostate cancer, and PNT2003, an SSTR therapy for treating patients with SSTR-positive neuroendocrine tumors. They are also developing MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease, LNTH-1363S, a fibroblast activation protein, alpha-targeted, copper-64 labeled PET imaging agent, and flurpiridaz, used to assess blood flow to the heart. The company has established collaboration agreements with several major players in the industry, including GE Healthcare, NanoMab Technology Limited, Curium, RefleXion Medical, Inc., POINT, Regeneron Pharmaceuticals, Inc, and Ratio Therapeutics LLC.

Founded in 1956 and headquartered in Bedford, Massachusetts, Lantheus Holdings, Inc. is a well-established company in the healthcare supplies sector, with a strong focus on developing innovative diagnostic and therapeutic products to improve patient outcomes. With its extensive product portfolio, robust pipeline, and strategic collaborations, the company is well-positioned to continue making significant contributions to the field of healthcare. For more information, please visit their website at https://www.lantheus.com. The company's stock is listed on the NASDAQ exchange under the ticker symbol LNTH, with the ISIN code US5165441032, and is classified under the GICS Sub Industry: Health Care Supplies.